Published in Biochim Biophys Acta on February 07, 2009
Parents' ages at birth and risk of adult-onset hematologic malignancies among female teachers in California. Am J Epidemiol (2010) 0.94
Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer (2010) 0.90
Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica (2011) 0.88
Medical genetics and epigenetics of telomerase. J Cell Mol Med (2011) 0.82
[Tumor stem cell research - basis and challenge for diagnosis and therapy]. Wien Klin Wochenschr (2010) 0.80
High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model. Cancer Immunol Immunother (2011) 0.77
Effects of PCB126 and PCB153 on telomerase activity and telomere length in undifferentiated and differentiated HL-60 cells. Environ Sci Pollut Res Int (2015) 0.76
Telomerase Activation in Hematological Malignancies. Genes (Basel) (2016) 0.75
Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci (2006) 1.25
Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. Blood (2009) 1.04
Apoptosome-independent pathway for apoptosis. Biochemical analysis of APAF-1 defects and biological outcomes. J Biol Chem (2003) 0.90
Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene (2004) 0.88
Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death. Oncogene (2003) 0.83
hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications. Mol Cancer Ther (2011) 0.81
The telomere story or the triumph of an open-minded research. Biochimie (2010) 0.80
A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT). Int J Cancer (2014) 0.80
Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominant-negative hTERT mutant. Mol Cancer Ther (2012) 0.79
Telomeres and telomerase: from basic research to clinical applications. Biochimie (2007) 0.79
Antitumor trans-N-heterocyclic carbene-amine-Pt(II) complexes: synthesis of dinuclear species and exploratory investigations of DNA binding and cytotoxicity mechanisms. J Med Chem (2013) 0.78
Activation of both protein kinase A (PKA) type I and PKA type II isozymes is required for retinoid-induced maturation of acute promyelocytic leukemia cells. Mol Pharmacol (2013) 0.77
[Cell death signalling: recent advances and therapeutic application]. Bull Cancer (2005) 0.77
cFos mediates cAMP-dependent generation of ROS and rescue of maturation program in retinoid-resistant acute promyelocytic leukemia cell line NB4-LR1. PLoS One (2012) 0.76
Diagnostics, prognostic and therapeutic exploitation of telomeres and telomerase in leukemias. Curr Pharm Biotechnol (2006) 0.76
Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide. FEBS Lett (2005) 0.75
[Current concepts on apoptotic signalling pathways: new targets for anticancer strategies]. Bull Cancer (2003) 0.75